vatreptacog alfa (activated)
Recombinant proteinexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00486278)
Timeline
Indications
Mechanism of action
- Coagulation factor VIISupplementation
F7 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108322 ↗
Also known as
- vatreptacog alfa
- vatreptacog alfa
- vatreptacog alfa (activated)
- vatreptacog alfa (activated)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01392547 | Phase 3 | Jul 1, 2011 | Novo Nordisk |
| NCT00822185 | Phase 1 | Jan 1, 2009 | Novo Nordisk |
| NCT00486278 | Phase 2 | Jun 1, 2007 | Novo Nordisk |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 3 | 3 | 3 | 2007 |
1 organizations
Page 1 / 1